We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lowered by JPMorgan Chase & Co. from $47.00 to $45.00 in a research report released on Monday,Benzinga reports. JPMorgan Chase ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Commonwealth Equity Services LLC trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.2% in the ...

Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA ...

As a leading biotech company, BIIB benefits from an impressive pipeline of drugs including TECFIDERA, VUMERITY, AVONEX, SPINRAZA, SKYCLARYS, and QALSODY. However, BIIB’s performance remains ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...